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Abstract 
Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucina-
tions, and sleep paralysis. This disease affects significantly the overall patient functioning, interfering with social, work, 
and affective life. Some symptoms of narcolepsy depend on emotional stimuli; for instance, cataplectic attacks can 
be triggered by emotional inputs such as laughing, joking, a pleasant surprise, and also anger. Neurophysiological 
and neurochemical findings suggest the involvement of emotional brain circuits in the physiopathology of cataplexy, 
which seems to depending on the dysfunctional interplay between the hypothalamus and the amygdala associ-
ated with an alteration of hypocretin levels. Furthermore, behavioral studies suggest an impairment of emotions 
processing in narcolepsy-cataplexy (NC), like a probable coping strategy to avoid or reduce the frequency of cata-
plexy attacks. Consistently, NC patients seem to use coping strategies even during their sleep, avoiding unpleasant 
mental sleep activity through lucid dreaming. Interestingly, NC patients, even during sleep, have a different emotional 
experience than healthy subjects, with more vivid, bizarre, and frightening dreams. Notwithstanding this evidence, 
the relationship between emotion and narcolepsy is poorly investigated. This review aims to provide a synthesis of 
behavioral, neurophysiological, and neurochemical evidence to discuss the complex relationship between NC and 
emotional experience and to direct future research.
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Introduction
Narcolepsy is a chronic debilitating sleep disorder affect-
ing humans and animals, characterized by excessive 
daytime sleepiness (EDS), cataplexy, hypnagogic hal-
lucinations, and sleep paralysis. EDS consists of daily 
periods of an irrepressible need to sleep that leads to 
real sleep attacks, and is exacerbated by periods of rela-
tive physical inactivity (e.g., watching television, driving 
car, etc.). Also, the premature occurrence of REM sleep 
onset (SOREMs) characterizes these sleep episodes [1, 
2], representing an essential element for diagnosing nar-
colepsy [3]. It should be underlined that unlike EDS, that 
may also occur in other disorders, cataplexy is a pathog-
nomonic symptom of narcolepsy. It consists of a sudden 
drop in muscle tone, total or partial, triggered by intense 
emotions, especially those leadind to laughters, but also 
excitement and anger [4–9]. These attacks can last from 
a few seconds to a few minutes, during which the patient 
remains conscious but unable to move. These symptoms 
are necessary to diagnose narcolepsy [3], while hypna-
gogic hallucinations and sleep paralysis are considered 
auxiliary symptoms. Hypnagogic hallucinations are 
dream-like hallucinations that occur at sleep onset and 
can be very scary because the patient is not aware of their 
hallucinatory nature. Sleep paralysis, often associated 
with hallucinations, is an inability to move limbs, head, 
or to breathe normally, and can be frightening and even 
terrifying, especially the first time.
In the past, narcolepsy has been classified in two sub-
types: narcolepsy with and without cataplexy [10]. This 
symptom-based diagnosis has become unconvincing 
due to the discovery of the role of hypocretin/orexin in 
cataplexy (hereafter referred to as “hypocretin”). The 
narcolepsy with cataplexy (NC) is associated with a low 
concentration of hypocretin in cerebrospinal fluid (CSF), 
while a normal hypocretin concentration in CSF appears 
Open Access
Behavioral and
Brain Functions
*Correspondence:  luigi.degennaro@uniroma1.it 
Department of Psychology, University of Rome “Sapienza”, Via dei Marsi, 
78, 00185 Rome, Italy
Page 2 of 11Schiappa et al. Behav Brain Funct           (2018) 14:19 
to characterize the narcolepsy without cataplexy (N) 
[11–13]. Nevertheless, a small population of patients 
with hypocretin deficiency does not manifest cataplexy at 
the time of diagnosis [14, 15]. Considering the involve-
ment of hypocretin in this sleep disorder, ICSD-3 [3] 
changed the terminology to “narcolepsy type 1” (hypo-
cretin deficiency) and “narcolepsy type 2” (no hypocretin 
deficiency).
It should be noted that narcolepsy was described for 
the first time at the end of the nineteenth century [16–
18], and since the beginning some authors focused on 
the relationship between emotional factors and narco-
lepsy, especially within the psychoanalytic framework 
[19]. Psychoanalysis and the first studies on narcolepsy 
were almost contemporary. Freudian theories on dreams 
led to a psychoanalytic explanation of this sleep disorder 
[20]. Interestingly, in this framework, sleep was consid-
ered a temporary escape from reality, and narcolepsy, 
with its unusual symptoms, was interpreted as related to 
some psychological condition. For instance, cataplectic 
attacks are often triggered by emotions, while frightening 
contents often characterize sleep paralysis and hallucina-
tions. Also, often the symptoms first appear during the 
psychologically and sexually turbulent years of adoles-
cence. In the light of above, it was hypothesized that nar-
colepsy could be considered a defense against anxiety and 
uneasiness associated with difficult personal issues. Some 
authors also investigated the clinical and personal sto-
ries of these patients, confirming the hypothesis of a link 
with emotional issues [e.g., 21]. However, these theories 
suggested sexual deviations and psychopathic personal-
ity structures as the underlying factors of narcolepsy [22, 
23]. An involuntary consequence of this view was that 
narcoleptic patients might develop a sense of guilt over 
their symptoms.
At the end of the 1990s, the deficit in hypothalamic 
hypocretin neurotransmission as the main determinant 
of narcolepsy was discovered, and this disorder was 
established as an organic brain disease [24–26]. Narco-
lepsy has long been described as characterized by high 
co-morbidity for psychiatric disorders [27], often mak-
ing the diagnosis difficult and delaying it. Nevertheless, 
it is still unclear if psychiatric symptoms are the result of 
the chronic disabling nature of the disease, or a “shared 
pathophysiology”, or a combination of both [28]. The 
current literature revealed that a high percentage of nar-
coleptic patients suffer from depression (57%) [29–31]. 
This co-morbidity may be due to the significant overlap 
in symptoms [31–33]. However, purely depressive symp-
toms like anhedonia, pathological guilt, and crying also 
occur in patients with narcolepsy [31]. Therefore, shared 
pathophysiology related to a hypocretin deficiency should 
be considered. For instance, lowered levels of hypocretin 
in post-mortem histopathological studies were found in 
depressed patients who completed suicide [34], but these 
findings have been inconsistent in other studies [35]. 
Also, the anxiety disorder has been reported in the 53% 
of patients with narcolepsy [32], but available studies are 
still relatively scarce. Lastly, comorbid schizophrenia and 
narcolepsy has been found, but the relationship between 
these diseases is controversial and potentially mislead-
ing because of the significant overlap of the hallucinatory 
phenomena [36–39]. The occurrence of psychotic and 
hallucinatory symptoms in narcolepsy has been reported 
as responsible for delayed diagnosis due to a misdiag-
nosis of schizophrenia [40–44]. In this respect, recent 
studies found that the comorbidity appears to be rare, 
underlying that further investigations should be carried 
out to improve diagnostic accuracy [45–47].
Although psychoanalytic theories proposed extreme 
etiological theories, and some symptoms of narcolepsy 
do depend on emotional stimuli, the relationship between 
emotion and narcolepsy is poorly investigated. On a 
general level, several studies examined the interaction 
between sleep and emotional regulation [for a review, 
48], and sleep deprivation protocols demonstrated the 
association between sleep loss and daytime negative 
emotional consequences [e.g., 48–52]. Poor sleep quality 
is linked to increased negative emotions and decreased 
positive emotions [53–55], with patients suffering from 
insomnia showing negative mood more than good sleep-
ers, especially in the evening [56]. Idiopathic nightmares 
are linked to psychological distress [57] and an alex-
ithymia personality style [58]. Anxiety may increase the 
occurrence of somnambulism [59].
The link between sleep and emotions also emerges in 
the field of clinical psychiatry. It is difficult to identify any 
mental health condition with symptoms related to mood 
or emotion in which sleep disturbance is not listed as a 
formal symptom or a common feature of the condition 
[60], such as in major depression and post-traumatic 
stress disorder (PTSD).
To sum up, it could be stated that in narcolepsy the 
relationship between sleep and emotional factors is par-
ticularly robust, mainly because the symptoms seem to 
be exacerbated by emotional states. In this review, we 
discuss the complex relationship between NC and emo-
tional experience, providing a synthesis of behavioral, 
neurophysiological and neurochemical evidence.
Methodological note
Studies were identified via PUBMED queries. Key search 
terms included:
– “Narcolepsy” and ‘‘cataplexy’’ in title/abstract (1435 
articles);
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– ‘‘Narcolepsy’’ and ‘‘emotions’’ in title/abstract (55 arti-
cles);
– “Narcolepsy” and “dream” in title/abstract (53 arti-
cles);
– “Narcolepsy” and “health” in title/abstract (197 arti-
cles).
We grouped the identified articles in the following 
categories:
1. Clinical aspects, diagnostic criteria, psychiatric 
comorbidity and life quality of narcolepsy;
2. Cataplexy: (a) clinical aspects, (b) role of the limbic 
system, (c) hypocretin deficit, (d) role of emotions, 
(e) emotional stimuli processing and coping strate-
gies;
3. Dreaming in narcolepsy.
We focused on the role of emotionality in narcolepsy, 
excluding non-English articles. All the articles resulting 
from using this method and related to our focus were 
included. Following these criteria, we identified 64 publi-
cations which were estimated to be of interest for further 
examination.
Physiopathology of cataplexy
It is well known that in NC patients the sudden drop 
in muscle tone is triggered by emotional factors such 
as laughing, joking, a pleasant surprise, and also anger 
[4–9]. This clinical feature suggests a close interaction 
between emotions and related anomalies in NC brain. 
For instance, neurophysiological evidence revealed 
a possible involvement of the amygdala in cataplexy. 
The amygdala is a limbic structure critically involved in 
emotional information processing in both animals and 
humans, as shown by neuroimaging, neurophysiological, 
and clinical studies (see [61–63]).
In the 1960s, the hypothesis of an involvement of this 
cerebral area in NC symptoms was proposed [64]. The 
first animal studies provided evidence for a relationship 
between alterations of amygdala and narcolepsy [e.g., 
65, 66]. For instance, Siegel et al. [65] found elevated lev-
els of axonal degeneration in the amygdala of narcolep-
tic dogs, which preceded or coincided with the disorder 
onset. This finding is coherent with the major symptoms 
of narcolepsy. An electrophysiological study on narcolep-
tic dogs [66] found a subpopulation of amygdala neurons 
associated with cataplexy, which significantly changed in 
activity before and during cataplectic attacks. This could 
have a role in mediation or modulation of these symp-
toms. Also, several human studies investigated the role of 
the amygdala in cataplexy. Hong et al. [67] used the Sin-
gle Photon Emission Computed Tomography (SPECT) to 
localize cerebral perfusion differences during cataplexy. 
They found a hyperperfusion in the right amygdala dur-
ing cataplectic attacks. However, this study included only 
two subjects. A recent functional magnetic resonance 
imaging (fMRI) study investigated the brain structures 
whose neural activity is specifically associated with emo-
tion-induced cataplexy in 21 children/adolescent with 
NC [68]. Cataplectic attacks were elicited in 10 patients 
by using funny videos. The study showed an increase in 
blood oxygen level-depend signal in the amygdala dur-
ing cataplectic attacks. Indirect evidence of amygdala 
involvement in NC also comes from psychophysiologi-
cal research. Khatami et  al. [69] investigated emotional 
process in NC and, in particular, emotional modulation 
of acoustic startle reflex (ASR) during the presentation 
of positive, neutral, and negative pictures selected from 
the International Affective Picture System (IAPS). The 
ASR is a kind of startle response triggered by threaten-
ing stimuli, and has been found to be dependent on lim-
bic structures such as the amygdala in both animal and 
human studies [70–73]. The measurement of ASR allows 
assessing the role of the amygdala in NC. The results 
showed the absence in NC patients compared to controls 
of a startle potentiation to unpleasant stimuli, supporting 
the hypothesis of an amygdala dysfunction in this sleep 
disorder.
It should be considered that the amygdala is not the 
only limbic structure implicated in cataplexy. Indeed, 
several studies showed the involvement of the hypo-
thalamus, considering it as the second main suprapon-
tine brain site whose dysfunction might contribute to 
cataplexy. Joo et  al. [74] found in a SPECT study a sig-
nificant hypoperfusion in anterior hypothalamus in NC 
patients compared to controls. Also, an fMRI study [75] 
compared brain activity in NC patients and controls 
while they were exposed to humorous pictures, find-
ing a reduction of hypothalamic response and enhance-
ment of amygdala response in NC patients. These results 
suggested that cataplexy may depend on dysfunctional 
hypothalamic-amygdala interactions triggered by posi-
tive emotions. As mentioned above, narcolepsy has been 
found to be associated with a reduction or loss of the 
hypothalamic peptide hypocretin [76–82] that projects to 
the amygdala [83, 84]. The first evidence that hypocretin 
is involved in narcolepsy comes from animal models [22, 
85, 86]. More interestingly, the link between hypocre-
tin dysfunction and narcolepsy, and in particular NC, is 
also supported by human studies. Approximately 90% of 
patients with narcolepsy showed reduced levels of hypo-
cretin in CSF [11], and postmortem studies confirmed the 
lack of detectable levels of this peptide in the cortex and 
the pons, in which normal hypocretinergic projections 
are found [78, 79].
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Nevertheless, the dysfunction of the hypocretin sys-
tem was observed only in NC, while a normal hypocretin 
concentration in CSF seemed to characterize the narco-
lepsy without cataplexy [11, 81, 87]. However, some cases 
of hypocretin deficiency without cataplexy have been 
described [14, 15]. Some animal studies suggested that 
the hypocretin neurons receive abundant projections 
from the limbic system [83, 84, 88], providing evidence 
that this neuronal system has close interactions with 
systems that regulate emotions. Besides, several stud-
ies supported the hypothesis that hypocretin is involved 
in a wide range of neurobehavioral processes, especially 
in  situations of high motivational relevance [89]. Also, 
the hypocretin neurons activation was associated with 
acute stress [90], helping to organize stress responses, 
while chronic stress can disrupt hypocretin signaling in 
target regions [91]. Some studies found that the hypoac-
tivity of the hypocretin system could yield depression-
like symptoms and amotivational syndrome [90, 92–94]. 
Bearing in mind that NC is a chronic stress condition, 
the relationship between stress and hypocretin activation 
supports the hypothesis that neural input from the lim-
bic system to the hypocretin neurons may be implicated 
in the pathophysiology of cataplexy. This link is also sug-
gested by the role of emotional situations for cataplexy.
To sum up, neurophysiological and neurochemical 
findings indicate an implication of the limbic system in 
NC (e.g., [11, 67, 68, 74, 75]). Indeed, cataplexy seems to 
depend on dysfunctional hypothalamic-amygdala inter-
actions associated with an alteration of the hypocretin 
levels. Hence, the involvement of emotional brain net-
work in the physiopathology of cataplexy could explain 
why emotional inputs triggered cataplexy.
Cataplexy and emotions
Lazarus [95] stated that emotions represent the “wisdom 
of the ages”, providing time-tested responses to adaptive 
problems. Emotions arise when something important 
to us is at stake, but they do not force us to respond in 
specific ways, they only make certain responses more 
probable. This malleability allows us emotional regula-
tion, meaning processes that influence how we experi-
ence and express emotions [96]. This focus is particularly 
interesting for narcolepsy. Considering the crucial role of 
emotions in cataplexy [4–9], it could be hypothesized a 
relationship between emotional reactions and cataplexy 
attacks, mediated by coping strategies. In particular, 
coping strategies could consist of an emotional constric-
tion that serves as an adaptive response to ward off cata-
plexy [97, 98]. The strategy to keep down expression of 
their own emotions could reduce or suppress emotion-
related behaviors (e.g., laughing, crying) that usual trig-
ger cataplexy [97, 98]. This hypothesis is also supported 
by the relationship between disease duration and cogni-
tive responses to the emotional stimuli: a longer disease 
seems to be associated with cognitive suppression [98]. 
Consistently, a prospective study on children showed for 
the first time a reduction of cataplexy severity after about 
3 years after the NC onset [99].
With regards to cataplexy and coping strategies, 
some studies focused on the emotional reactions in NC 
patients using standard stimuli to elicit emotions and 
investigates the emotional stimuli processing in these 
subjects. Tucci et  al. [97] investigated the emotional 
visual stimuli processing in NC patients, using the IAPS 
[100–102]. Muscular, autonomic, and cognitive reactions 
were measured while the subjects were exposed to pic-
tures with positive, neutral and negative valence. They 
found that these reactions were attenuated in NC patients 
compared to controls. In particular, they showed the low-
est responses with negative pictures. Also, De Zambotti 
et al. [98] used the IAPS to investigate hemodynamic and 
behavioral responses during emotional visual stimulation 
in NC patients. The hemodynamic responses to pictures 
were the same for NC patients and controls, while differ-
ences were found for behavioral responses: NC patients 
reported lower arousal scores associated to positive and 
neutral stimuli, a status of less pleasantness induced by 
pleasant stimulation, lower valence scores associated 
to pleasant stimuli and lower score at the “focus on and 
venting of emotions” dimensions of coping. Another 
study investigated facial emotional expressions (fear, 
happiness and sadness) and emotional regulation strate-
gies using a self-rated questionnaire in NC compared to 
central hypersomnia without cataplexy and healthy con-
trols. No differences have been found among the groups, 
namely the NC showed a typical emotional judgment 
ability and emotional regulation strategies, contrary to 
the authors’ initial hypothesis [103] These findings are 
counterintuitive considering that several studies found 
that amygdala damage is related to impairment in recog-
nition of emotional facial expressions [104]. Neverthe-
less, metabolic changes of the amygdala in NC patients 
may be localized in only one hemisphere (i.e., the right 
hemisphere), being without any consequence on facial 
expression recognition [105]. Hence, the authors sug-
gested that normal functioning of the amygdala may be 
unnecessary to normal performance on this tasks and 
narcoleptic patients may recruit different networks to 
produce a normal recognition performance [103].
Other studies investigated the humor stimuli process-
ing in NC, considering that the most frequent emo-
tional trigger for the cataplexy seems to be the laughter 
[e.g., 8, 9]. For example, Susta et al. [106] used a proto-
col using audio recordings aimed to trigger laughter in 
NC patients and controls. They registered cortical brain 
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activity by quantitative electroencephalography (qEEG) 
source localization to calculate the sequence of brain 
areas involved in laughter processing. The results showed 
a different pre-laughter activation between NC patients 
and controls. The gyrus orbitalis, the gyrus rectus and 
the gyrus occipitalis inferior were activated in controls, 
and the gyrus paracentralis, the gyrus cingularis, and the 
cuneus were activated in the patients.
Some authors measured the H-reflex during emo-
tive stimuli, which relies on contraction of the flexors of 
the calf because of the excitation in the tibial nerve. The 
reflex was reduced during laughter in healthy subjects, 
giving the feeling of lack of strength [107]. It should be 
noted that this effect may have a role in cataplexy. The 
H-reflex is the only neurophysiological variable which 
is altered in this phenomenon, disappearing cataplectic 
attacks [108–110]. Another study investigated the neuro-
physiological effects of startle and laughter in NC [111]. 
They found a decrement of H-reflex during laughter, 
without differences between NC and controls and with 
increased startle response in NC [111].
Most of these studies clearly showed how reactions to 
emotional stimuli are different in NC patients compared 
to controls [87, 97, 98, 106]. Some works found emotional 
reactions significantly different between NC patients and 
controls in response to unpleasant situations [97, 111], 
while others in response to pleasant situations [98, 106]. 
The heterogeneous results among pleasant and unpleas-
ant stimuli may depend on methodological differences, 
like a different input use (e.g., visual, audio) or output 
measure (e.g., muscular, autonomic, cognitive, hemo-
dynamic and behavioral responses, qEEG, H-reflex). 
However, all these findings suggest an impairment in 
emotions processing in NC, raising the possibility that 
these alterations are part of compensatory strategies to 
avoid or reduce in frequency cataplexy attacks [97–99]. 
However, this hypothesis does not rule out the possibility 
that the impairment in emotions processing in NC could 
be in relation with the impairment of emotional brain 
network (e.g., [11, 67, 68, 74, 75]).
According to the appraisal theories, emotions depend 
on the personal evaluation of the events [112]. It has 
been demonstrated that appraisal can determine differ-
ent emotional reactions and modulate their intensity 
[113]. In other words, personal evaluation of situations as 
less pleasant or unpleasant could be the result of a cog-
nitive approach to minimize the impact of emotion, for 
instance through the suppression which is the attempt to 
decrease or inhibit emotion-expressive behavior [114]. 
Therefore, it could be hypothesized the same cognitive 
mechanism in NC patients who develop unware adaptive 
strategies to face emotions and, specifically, to avoid cata-
plectic attacks. These hypotheses on coping strategies in 
NC do not explain the increasing startle response in NC 
found by Lammers et al. [111]. According to the authors 
[111], these findings may depend on the brain or neuro-
chemical anomalies that characterized NC. For instance, 
axonal degeneration in the amygdala and the medial sep-
tum region was found in narcoleptic dogs [65], and both 
these areas are known to be involved in startle responses. 
Furthermore, an increased startle response could be 
explained by an altered adrenergic tone, that character-
ized both startle reflexes [115, 116] and cataplexy [117]. 
So Lammers et al. [111] speculated that the exaggerated 
startle response could be a side effect, an increased sensi-
tivity for adrenergic stimulation as partial compensation 
of their propensity for cataplexy.
Finally, it should be considered that all the studies men-
tioned have the limit of not evaluating cataplexy, but its 
apparent subclinical expressions. Namely, no cataplec-
tic attack was elicited during the experiments. This may 
be explained by the use of stimuli with lower emotional 
impact than real-world stimuli. Despite these subclini-
cal data, different patterns of emotional management 
and expression have been reported in NC compared to 
controls, which are probably linked to specific styles of 
coping.
Mental sleep activity in narcolepsy and emotional 
experience
Some studies showed that emotional features of dreams 
are related to the activation of the limbic system [118–
120]. However, it should be underlined that dreaming is 
a peculiar object of study because of the methodological 
limitation to a reliable access to the mental sleep activity 
(MSA), namely the products of mental processing dur-
ing sleep which are reported upon awakening in the form 
of dream report [121–123]. Microstructural analyses 
also found a link between emotional features in dreams 
and the limbic system, investigating the relationships 
between volumetric and ultrastructural measures of the 
hippocampus-amygdala complex and specific qualita-
tive features of dreaming [124]. In particular, bizarre-
ness of dream reports was negatively correlated with the 
left amygdala volume and positively correlated with the 
microstructural integrity (i.e., lower mean diffusivity) of 
the right amygdala, while emotional load was directly 
proportional to the microstructural integrity (i.e., lower 
mean diffusivity) of the left amygdala; on the other hand, 
the volume of the right hippocampus was negatively 
associated with bizarreness [124]. In other words, dream 
contents characterized by higher level of bizarreness 
were related with smaller left amygdala, smaller right 
hippocampus and lower mean diffusivity of the right 
amygdala, while dreams characterized by high emotional 
load were related to the low mean diffusivity of the left 
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amygdala. This finding was subsequently confirmed in 
another study on patients with Parkinson’s Disease (PD), 
showing for the first time in this population that the 
dopamine network plays a key role in dream experience. 
A higher dopamine agonist dosage was associated with 
qualitatively impoverished MSA, as expressed by lower 
bizarreness and emotional load values [125]. Alterations 
in dopaminergic levels also characterize narcolepsy, and 
indeed Modafinil is used to enhance vigilance in treat-
ment of this disease [126, 127] because of its ability to 
increase cerebral levels of dopamine [128, 129]. Keeping 
in mind the role of dopamine network in dreaming [125] 
and its impairment in narcolepsy [126, 127], it is possible 
to speculate that dream experience in this sleep disorder 
could be affected by neurochemical unbalance.
Considering all these findings [124, 125], the crucial 
role of emotions in narcolepsy [4, 6–9, 69, 97, 98, 106, 
111] and an impairment of the limbic system in these 
subjects (e.g., [11, 67, 68, 74, 75]), the investigation on 
emotional experience during MSA for this sleep disor-
der deserves interest. Narcoleptic patients often report 
an abundant production of vivid, bizarre and frightening 
MSA [130]. A high prevalence of aggressive dreams was 
found, including dreams with aggressive sexual themes 
[131]. Furthermore, some studies revealed that narcolep-
tic patients, with or without cataplexy, have more nega-
tively toned and bizarre dreams and significantly more 
terrifying and repetitive dreams in narcoleptic patients 
compared to insomnia patients [132]. However, it should 
be noted that some authors also found positive emotions 
in narcoleptic dreams [133]. Other authors [134] pos-
ited that NC exaggerates the emotional aspects of REM 
dreams, probably because of the alteration of neurobio-
logical systems that support cognitive-emotional func-
tions. They investigated the emotional experience during 
REM sleep in these patients and observed more intense 
emotions –especially- anxiety/fear and following joy/ela-
tion [134] and more bizarre and vivid contents [135].
Regarding the awareness of dreaming experience in 
these patients, a recent study investigated the prevalence 
of dream-reality confusion in NC. Dream delusions are 
extremely common in this disorder, and patients with NC 
were much more likely to report mistaking dream experi-
ences as true memories, in comparison with healthy con-
trols [136]. Conversely, other results suggested that these 
patients were more often aware of their state of con-
sciousness during dreaming than healthy subjects (i.e., 
they knew that the dream experience was not real) [133]. 
Furthermore, it was found a higher prevalence of lucid 
dreaming in NC and N patients, compared to healthy 
subjects [137, 138]. Lucid dreaming is the experience of 
being aware of dreaming while asleep and continuing to 
dream [139], and this awareness could be used to modify 
unpleasant narcoleptic dreams. Meaidi et al. [140] found 
a significant increase in lucid dreaming of N and NC 
compared to healthy controls, without any difference in 
emotional contents in the frequency of nightmares. Dif-
ferently, another study showed an increase of nightmares 
for these patients [141]. Pisko et  al. [141] showed that 
the prevalence of vivid but not unpleasant dreams for N 
and NC patients was 26%, with a higher frequency for 
NC patients. This study also found that the prevalence of 
nightmares was 33%, without difference between N and 
NC, while the prevalence of nightmares in general pop-
ulation was around 5% [142, 143]. According to Meaidi 
et al. [140], the intensification of lucid dreaming in N and 
NC patients compared to healthy controls could explain 
the low incidence of nightmares in the clinical group, sug-
gesting that lucid dream may be part of a coping strategy 
and may be useful to treat nightmare disorders. For this 
reason, the so-called “lucid dreams” have been repeatedly 
proposed as an effective therapy for nightmare disorder 
[144–146]. A strategy to induce lucid dreaming in healthy 
subjects is the wake-up-back-to-bed technique, in which 
subjects are awakened in the early morning hours and 
go back to sleep after a period of wakefulness [147, 148]. 
Perhaps, same narcoleptic sleep peculiarities (i.e., frag-
mented night sleep, SOREMs) might have similar effects 
to the wake-up-back-to-bed technique in healthy, pro-
moting cortical arousal that facilitated lucid dreaming.
It should be noted that narcoleptic patients, even dur-
ing sleep, have an emotional experience different from 
healthy subjects [113, 131, 134, 135, 141]. Interestingly, 
N and NC could use coping strategies also during their 
sleep, avoiding unpleasant MSA through lucid dreaming 
[138, 140]. Moreover, this kind of emotional experience 
during sleep, i.e., so vivid, bizarre and frightening [113, 
131, 132, 134, 135, 141], could be partly linked to an emo-
tional experience in waking state, like a possible conse-
quence of emotional inhibition and defensive attitude 
during the daytime. Finally, emotional experience dur-
ing MSA seems not influenced by the physiopathology of 
cataplexy, since there is no difference between N and NC 
[137, 138, 140, 141].
Future perspectives
Overall, the discussed results emphasize that the rela-
tionship between NC and emotional processes is still 
poorly understood. On this basis, some further consid-
erations and insights for future studies seem appropriate.
Firstly, considering the hypothesis about the coping 
strategies of patients with NC, further investigations 
are necessary to understand which strategy should 
be applied and to what extent this could represent an 
adaptive behavior by modulating the occurrence of 
symptoms. In this vein, the ability to express emotions 
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may affect cataplexy, and the presence/absence of alex-
ithymia in NC should be assessed. A study reported a 
higher score on Toronto Alexithymia Scale-20 (TAS-
20) [149] in a group of narcoleptic patients than in a 
control group [58]. These patients could actively con-
trol the expression of their emotions, avoiding a con-
tact with their emotions to prevent some unpleasant 
symptoms, like cataplexy attacks for NC. This view-
point becomes promising especially considering that 
NC is a chronic disorder and it could be associated with 
a secondary form of alexithymia, as an attempt to cope 
with the stress of situation (e.g., [150–153]). In other 
words, secondary alexithymia could be considered as a 
consequence of the illness-related stress, like a defense 
mechanism against highly emotional events [153, 154].
Moreover, subjects with narcolepsy can experience a 
gradual reduction of quality of life and exposed to an 
increased risk of work-related and transit accidents, 
sexual dysfunctions and neuropsychological alterations 
[155, 156], developing dysfunctional coping strategies. 
For these reasons, it could be expected that alexithymia 
levels change during NC progression. In this vein, alex-
ithymia levels should be assessed in different phases of 
the disease, by longitudinal designs aimed to investigate 
if and how emotional awareness and expression change 
as symptoms progress.
Moreover, alexithymia may be related to dream alter-
ations in NC [113, 131, 134, 135, 141]. Although not 
completely consistent, some independent findings on 
alexithymia compared to healthy subjects suggested 
that dream recall rate was lower and more impov-
erished [58, 157–165], while nightmares were more 
frequent or distressing [58, 164, 166]. Since the rela-
tionship between alexithymia and dreaming involves 
processes regulating emotion during both wakefulness 
and dreaming, this issue should be further addressed.
Furthermore, we have underlined that subjects with 
NC report qualitatively rich dream contents [113, 131, 
135, 141, 166], suggesting that emotional memory con-
solidation in these patients is not compromised. In this 
respect, we have to consider that alteration of the lim-
bic network in these patients (e.g., [20, 67, 68, 74, 75]) 
and the findings on the neural substrates of dreaming 
[124, 125] are not always consistent. For instance, the 
emotional load characterizing the core symptoms of 
PTSD-such as nightmares-seems to be related to the 
hyperactivation of the amygdala [167, 168]. Also, REM 
sleep could amplify the altered function of the amyg-
dala [168]. Several functional neuroimaging human 
studies revealed that emotional network, including the 
amygdala, was activated during REM sleep [118, 169–
172], even if these studies still were based on the equa-
tion “REM sleep = dreaming”.
Moreover, a stereo-EEG study on pharmaco-resist-
ant epileptic patients found a transient activation of the 
amygdala which was time-locked to the onset of REM 
sleep, suggesting that this activation may be involved in 
adding an emotional tone to dream contents [173]. Also, 
recent investigations confirmed the relationship between 
some structural parameters of the amygdala and the hip-
pocampus and the emotional load of dream reports [124, 
125]. Taken together, these findings support the hypoth-
esis that the activation of the limbic system may play a 
crucial role in the dreaming, but how the impairment of 
the limbic system affects MSA in NC is still unknown. 
In our opinion, this issue requires further investigations. 
Furthermore, studies on emotional experience during 
MSA did not find differences between N and NC [137, 
138, 140, 141], suggesting that this is not influenced by 
the physiopathology of cataplexy. Hence, studies that 
investigated in N and NC the specific role of hypocretin 
during MSA also are needed.
Finally, it should be mentioned that EEG studies pro-
vided some indications about the relationship between 
brain networks and emotional memories. In particular, 
the prefrontal theta activity during REM sleep has been 
related to emotional memory consolidation [174]. The 
same EEG activity (5–7 Hz) during REM sleep predicted 
the subsequent dream recall, suggesting shared mecha-
nisms in the retrieval of episodic memory across differ-
ent states of consciousness [175, 176]. However, in NC 
just a few studies have been carried out to identify EEG 
correlates of dreaming. To the best of our knowledge, the 
only study in this direction found a relationship between 
the gamma EEG activity and lucid dreams, and also a 
reduced delta activity seems related to the lucidity of 
dreams [138]. This result is not coherent with the studies 
mentioned above [175, 176], while supports the view of a 
direct relation between dream recall rate and decreased 
cortical activation [177, 178]. According to these con-
siderations and to the fact that NC patients show higher 
dream recall rate than healthy population [137, 138, 
179], we suggest that other studies should be developed 
to investigate the EEG correlates of dream recall in this 
population, examining -specifically- the relation between 
EEG pattern and emotional dream contents.
Concluding remarks
This review summarizes the studies on the relationship 
between emotional experiences and narcolepsy. Neuro-
physiological and neurochemical findings support the 
hypothesis of the involvement of the limbic system in the 
physiopathology of cataplexy [e.g., 20, 67, 68, 74, 75], and 
this could explain the relationship between cataplexy and 
emotional inputs. Furthermore, behavioral studies sug-
gest an impairment in emotions processing in NC, like a 
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possible coping strategy to avoid or reduce in frequency 
cataplexy attacks [97, 98, 106] and, consistently, these 
patients could use these coping strategies even during 
sleep, avoiding unpleasant MSA through lucid dream-
ing [138, 140]. Moreover, about dreaming in NC, we have 
pointed out that these patients report peculiar dream 
contents, characterized by more vivid, bizarre and fright-
ening contents than those of healthy subjects [113, 131, 
134, 135, 141]. Therefore, emotional memory consolida-
tion seems not being altered, although several studies 
suggest the impairment of the limbic system in this dis-
ease (e.g., [20, 67, 68, 74, 75]).
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